Innovation drives everything

Dr. Falk Pharma – the experts in digestive and metabolic medicine


Dr. Falk Pharma – Innovation drives everything

As a research-based family business with global presence, we focus on the development and distribution of innovative medicines that improve patients’ health and well-being. For over 60 years. 
Our focus: To enable relief, well-being, more ease of movement and confidence in everyday situations for millions of people with inflammatory bowel disease as well as digestive and metabolic problems. With the best possible therapies.

Falk Foundation provides a platform for experts in the fields of gastroenterology and hepatology to meet and communicate with one another.

Innovation drives everything

Dr. Falk Pharma – the experts in digestive and metabolic medicine

Learn more

Knowledge drives everything

Falk Foundation – scientific dialogue to advance therapeutic progress

Learn more


What’s happening at Dr. Falk Pharma? Visit our Newsroom and follow us on social media for the latest news, press releases, clinical trial announcements, upcoming events and more from Dr. Falk Pharma.


B2Run 2024


Starting together with our colleagues from Losan Pharma in Freiburg!



EASL 2024


From 5-8 June 2024 in Milan - we look forward to seeing you (exhibition space E2)


Corporate, Press release

New Addition to the Management Board


The new Technical Operations business unit will be headed up by Dr. Andreas Rascher


Information for patients


Primary biliary cholangitis

Helping patients to understand their disease this brochure gives a comprehensive overview on primary biliary cholangitis.

Authors: Prof. T. Berg, Dr. T. Herta


Autoimmune hepatitis

By providing a comprehensive overview of autoimmune hepatitis, this brochure helps patients understand their disease.

Authors: Prof. Dr. H. Bantel, Prof. Dr. H. Wedemeyer


Microscopic colitis

Up-to-date information for people suffering from microscopic colitis – a chronic inflammatory bowel disease.

Information for health care professionals

Foundation event

Gut Microbiome: Structure, Metabolic Activity And Clinical Application

The online event replacing the Falk Symposium in Sydney focused on microbial profiling and the challenges of microbiome manipulation. Watch all three sessions on demand.

Foundation event

Panel Discussion: FMT – the Global Perspective

The panel discussion held during the digital ‘Gut Microbiome’ event explored the options for a consensual view on Fecal microbiota transplantation.


The Falk Foundation organizes and supports scientific dialogue to advance therapeutic progress. We facilitate exchange of knowledge within the field of digestive and metabolic medicine through a wide range of platforms that are always comprehensive, up-to-date, and independent.

Common indications

Get informed on various diseases of the liver, the biliary tract, the intestinal tract as well as the esophagus with details on symptoms, course of the disease, diagnosis and treatment options.

All indications

Eosinophilic esophagitis is a rare disease of the esophagus involving chronic inflammation as well as difficulty and pain swallowing. The symptoms of the disease seriously affect quality of life. As the disease is progressive, long-term treatment is necessary.


Microscopic colitis consists of two conditions called lymphocytic colitis and collagenous colitis. It is an inflammatory bowel disease and primarily impacts the large intestine. Microscopic colitis can only be diagnosed by examining tissue samples under a microscope, colonoscopy findings are typically normal.


Primary biliary cholangitis (PBC) is a chronic autoimmune disease in which the small bile ducts are damaged by inflammation. Without adequate treatment, this inflammation may eventually spread to the tissue of the liver and even cause cirrhosis. PBC affects women much more often than men.